Express Pharma Pulse

India's No.1 Weekly For The Pharmaceutical Industry

About us || Feedback|| Advertising || Subscribe || Archives / Search

Issue dated - 1st Jan. 2004

Latest News

Aurobindo gets EDQM nod for domperidone and domperidone maleate
July 21st, 2005, 19:14:34 hrs IST
Symposium on patient safety and pharmacists to be held on July 27
July 21st, 2005, 16:59:13 hrs IST
Technology transfer conference on July 29-30
July 21st, 2005, 16:53:50 hrs IST
NICB acquires Ocimum\'s Biotracker LIMS
July 15th, 2005, 20:02:52 hrs IST
Ranbaxy gets FDA tentative approval for zidovudine generic
July 15th, 2005, 19:56:03 hrs IST

News Archives >>

Centre to seek NRI support for stepping up R&D fund

PCI to harmonise curricula across Asia

Clearer patent law provisions required to benefit from WTO regime: Experts

INSIDE PHARMA

MARKET PLACE

EDITORIAL

OPED

CORPORATE

PRODUCTS

TECHNOLOGY TRENDZ

HAPPENINGS

CLINCAL RESEARCH

PROFILE

BOOK REVIEWS

NEWS

CONVERSATION

MKT. RESEARCH - GLOBAL

BULK DRUGS MAKERS LIST

ESSENTIAL DRUGS LIST

Pharma Research
(Adobe PDF file)

MARKET PLACE	EDIT
Marketing audit: Augumenting effectiveness in sales The tools selected for measuring the marketing effectiveness should be precise and based upon empirical data, says C R Chenthir K	Editorial Safety bypassed Edit Article CROs: Beneficial to Indian patients
OPED	TECHNOLOGY TRENDZ
Essential drugs and rational drug use With limited resources at the disposal of health care facilities, it is important to improve the management of existing resources, says Guru Prasad Mohanta	Power of packaging in pharma industry Oden’s mass/blend system - How it works ‘SMEs will benefit greatly by adopting
CORPORATE	HAPPENINGS
Novartis modifies GIPAP with immediate effect Ranbaxy granted first USFDA approval for Ceflaclor tablets NPIL buys-out partner’s 50 pc stake in Sarabhai for Rs 693 million Strides net profit at Rs 6.32 crores, sales at Rs 275.90 crores	New disciplines and directions in drug development News in brief
IN THE NEWS	CONVERSATION
Diabetologists prefer multi-drug therapy Though the anti-diabetes market in India indicates a growing preference for combination therapy, diabetologists — the mainstay of the anti-diabetic prescribing population, prefer to co-prescribe oral hypoglycemic agents (OHAs), according to a report by ACNielsen ORG-MARG Pharma.	‘Companies are very reluctant to part with their data’ The National Pharmaceutical Pricing Authority (NPPA), under the Department of Chemicals & Petrochemicals is about to enter a phase in which it will have to chart out strategies for addressing the challenges in the upcoming WTO regime.

For
JOB OPTIONS
Click here